The Claim
In older adults with ischemic systolic heart failure, daily administration of 10 mg rosuvastatin for 32.8 months does not result in a statistically significant improvement in functional status as measured by New York Heart Association class or patient-reported quality of life using the McMaster Overall Treatment Evaluation questionnaire.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In older adults with a type of heart failure caused by reduced pumping ability, taking 10 mg of rosuvastatin daily for about 2.7 years does not lead to measurable improvements in heart function or quality of life.
See the scientific wording
In older adults with ischemic systolic heart failure, daily 10 mg rosuvastatin does not significantly improve functional status as measured by New York Heart Association class or patient-reported quality of life using the McMaster Overall Treatment Evaluation questionnaire over 32.8 months of treatment.
Rosuvastatin lowers cholesterol and reduces inflammation in the blood, which improves blood flow in small vessels of the heart and reduces hospital visits. However, it does not change how well the heart pumps or how patients feel about their daily abilities.
What the research says
1 studyStudy: Rosuvastatin in older patients with systolic heart failure.
Taking rosuvastatin for nearly three years didn't make heart failure patients feel better or able to do more daily activities, even though it lowered cholesterol and reduced hospital visits a bit.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.